Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
出版年份 2021 全文链接
标题
Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
作者
关键词
-
出版物
Clinical Pharmacology in Drug Development
Volume 10, Issue 9, Pages 1028-1043
出版商
Wiley
发表日期
2021-06-13
DOI
10.1002/cpdd.951
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects
- (2020) Meng-na Wang et al. INVESTIGATIONAL NEW DRUGS
- Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
- (2019) Andreas Becker et al. CTS-Clinical and Translational Science
- Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development
- (2019) Mariam A. Ahmed et al. CTS-Clinical and Translational Science
- Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer
- (2019) B. van Veggel et al. LUNG CANCER
- Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR -Mutated Non–Small Cell Lung Cancer
- (2017) Pei Ni Ding et al. Journal of Thoracic Oncology
- ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase ( ALK )-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
- (2017) Byoung Chul Cho et al. Journal of Thoracic Oncology
- Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment
- (2017) Vanita Noronha et al. OncoTargets and Therapy
- Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
- (2016) Yoshihisa Kobayashi et al. CANCER SCIENCE
- Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects
- (2015) Yvonne Y. Lau et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors
- (2014) V. Hirsh et al. Current Oncology
- Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients
- (2013) Monic Roengvoraphoj et al. CANCER TREATMENT REVIEWS
- Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
- (2013) Geoffrey R. Oxnard et al. Journal of Thoracic Oncology
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
- (2013) M. E. Arcila et al. MOLECULAR CANCER THERAPEUTICS
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
- (2011) Richat Abbas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers
- (2011) Kenji Tomizawa et al. LUNG CANCER
- A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors
- (2010) E I Heath et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
- (2009) H. A. Burris et al. CLINICAL CANCER RESEARCH
- Current Methods for Predicting Human Food Effect
- (2008) Kimberley A. Lentz AAPS Journal
- Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response
- (2008) J.-Y. Wu et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started